本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。千呼万唤始出来,亚盛医药的第二颗“重磅炸弹”利生妥(通用名:利沙托克拉;研发代码:APG-2575)终于落地。7月10日,中国国家药监局(NMPA)官网最新公示,亚盛医药自主研发的新型选择性Bcl-2抑制剂利生妥获NMPA附条件批准上市,用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小...
Source Link本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。千呼万唤始出来,亚盛医药的第二颗“重磅炸弹”利生妥(通用名:利沙托克拉;研发代码:APG-2575)终于落地。7月10日,中国国家药监局(NMPA)官网最新公示,亚盛医药自主研发的新型选择性Bcl-2抑制剂利生妥获NMPA附条件批准上市,用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.